Healthcare shares were flat to higher in pre-market trade
In healthcare stocks news, Pluristem (
), a developer of placenta-based cell therapies, was more than 6%
higher Thursday after the company said the FDA has reviewed
Pluristem's comparability studies of its PLacental eXpanded (
) cell products and granted approval for the company to manufacture
these products in its new commercial-scale cell manufacturing
And, Threshold Pharmaceuticals (
) was down about 2% after it reported that for Q4, the company
widened its loss year over year, and missed analysts' expectations,
while revenue was in line with Street estimates.
The biotechnology company reported a Q4 GAAP loss of $0.13 per
share, compared with the prior-year period's $0.10 loss per share.
Revenue was $3.2 million, up from $2.02 million in the same quarter
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.